1 de 10 sur environ 39 communiqués.
Myovant Sciences, Inc.
84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year82.8% average reduction from baseline on the Numerical...
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the...
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief...
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix),...
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David...
Myovant Sciences, Inc.
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront payment...
Myovant Sciences, Inc.
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO studyConference call and webcast to be held on December...
Myovant Sciences, Inc.
BASEL, Switzerland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public...
1 de 10 sur environ 39 communiqués.
